<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0006775'>Multiple myeloma</z:hpo> (IgG kappa + IgA kappa type, clinical stage IA) was diagnosed in a 82-year-old woman in January 1986 </plain></SENT>
<SENT sid="1" pm="."><plain>Chemotherapy (melphalan, <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, <z:chebi fb="0" ids="36373">vindesine</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>), caused prolonged <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore she was given other treatment </plain></SENT>
<SENT sid="3" pm="."><plain>In October 1992, her peripheral blood examination demonstrated 2% blastic cells and 12% eosinophils </plain></SENT>
<SENT sid="4" pm="."><plain>Bone marrow <z:hpo ids='HP_0002835'>aspiration</z:hpo> showed dysplastic features of trilineage blood cells with 4.8% myeloblasts </plain></SENT>
<SENT sid="5" pm="."><plain>The karyotype of bone marrow cells from this patients was 47, XX, +der(1)t(1;7) (p11;p11), -7, +8 </plain></SENT>
<SENT sid="6" pm="."><plain>A diagnosis of therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo>) was established </plain></SENT>
<SENT sid="7" pm="."><plain>Eleven months after diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, she is alive without leukemic transformation </plain></SENT>
</text></document>